Lantheus Holdings

Traded on the St. Petersburg Stock Exchange
Lantheus Holdings, Inc. develops, manufactures, sells, and distributes diagnostic medical imaging agents and products. The Company offers imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases.
Lantheus Holdings stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Lantheus Holdings balance sheet

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Lantheus Holdings cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Lantheus Holdings multipliers

Report period2017 2018 2019 2020 2021 2022
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Lantheus Holdings profitability

Report period2017 2018 2019 2020 2021 2022
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Lantheus Holdings assets
Lantheus Holdings cash flows

Lantheus Holdings shares

TickerNameTypeNominal valueISINPrice
LNTH:USLantheus Holdings, Inc.Common share-US5165441032$59.02
Lantheus Holdings news
29.04.2022
Lantheus Holdings' GAAP net income for 3 months of 2022 was $42.962 million, up 4.77 times from $9.008 million in the previous year. Revenue increased 2.26 times to $208.88 million from $92.509 million a year earlier.
Source: {source} pictogram investor.lantheus.com
Pictogram next
24.02.2022
Lantheus Holdings' GAAP loss for 2021 was $71.279 million, up 4.3 times from $13.473 million in the previous year. Revenue increased 25.3% to $425.208 million from $339.41 million a year earlier.
Source: {source} pictogram investor.lantheus.com
Pictogram next
23.02.2022
FDA has certified Lantheus Holdings' DEFINITY manufacturing facility to improve the efficacy of ultrasound diagnostics for patients with abnormal echocardiograms. The 16,000-square-foot facility is located in Massachusetts. The plant's capacity covers the company's current drug production needs with reserve.
Source: {source} pictogram investor.lantheus.com
Pictogram next
04.11.2021
Lantheus Holdings' GAAP loss for 9M 2021 was $31.064 million, up 3.1 times from $10.061 million in the previous year. Revenue increased 20.5% to $295.646 million from $245.258 million a year earlier.
Source: {source} pictogram investor.lantheus.com
Pictogram next
All Lantheus Holdings news
General information
Company nameLantheus Holdings
SectorHealth Care / Health Care Equipment & Services / Health Care Equipment & Supplies / Health Care Supplies
Business address331 TREBLE COVE ROAD NORTH BILLERICA MA 01862 978 671-8001
Mailing address331 TREBLE COVE ROAD NORTH BILLERICA MA 01862
Websitewww.lantheus.com
Information disclosurewww.sec.gov